BMS
Bristol-Myers Squibb appoints Charles Bancroft acting chief financial officer
January 15, 2010Sales and Marketing BMS, appointment, sales and marketing
Charles Bancroft has been appointed acting chief financial officer at Bristol-Myers Squibb, replacing Jean-Marc Huet who left the company at …
BMS and Pfizer will file apixaban in Europe next year
December 8, 2009Sales and Marketing BMS, Pfiizer, Pfizer, VTE, apixaban
Bristol-Myers Squibb and Pfizer are to submit their new anti-clotting drug for European approval in the first half of next …
AZ-BMS launch Onglyza in Europe
October 19, 2009Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …
Manufacturing facility news in brief
September 14, 2009Manufacturing and Production BMS
Pharmafocus' round-up of manufacturing facility news includes plant disposals by BMS and Sanofi-Aventis, a new build for device company Haselmeier …
BMS profits surge ahead
July 30, 2009Sales and Marketing BMS
Bristol Myers-Squibb's earnings growth massively outstripped its income in the second quarter of the year. The company saw its net …
BMS buys Medarex for $2.1 billion
July 24, 2009Research and Development, Sales and Marketing BMS, MA, Medarex
Bristol-Myers Squibb is to spend $2.1 billion in buying Medarex, the human antibody drug discovery specialists. Princeton-based Medarex is best …
BMS launches cancer website
July 15, 2009Medical Communications, Sales and Marketing BMS, Cancer, digi
Bristol-Myers Squibb has launched a new website for sufferers of chronic myeloid leukaemia (CML), a cancer of the blood. MyCMLCare.com …
Onglyza and Cimzia recommended by CHMP
July 2, 2009Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza
Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …
BMS turns in solid first quarter results
May 1, 2009Sales and Marketing BMS
Bristol-Myers Squibb turned in respectable figures for the first quarter of 2008, with net income up 5% to $921 million. …
Plavix sales help BMS into profit
January 29, 2009Sales and Marketing BMS, Plavix
Strong fourth quarter sales of its blockbuster blood thinner Plavix have helped Bristol-Myers Squibb back into the black. Net earnings …
BMS denies further 10% staff cut
January 2, 2009Sales and Marketing BMS, restructure
Bristol Myers Squibb has denied claims it is making a further 10% reduction to its work force, and said any …
BMS to cut extra 10% from workforce
December 17, 2008Sales and Marketing BMS
Bristol-Myers Squibb is to cut its global workforce by an extra 10% before 2010, in order to reduce costs and …
BMS breast cancer drug rejected
November 27, 2008Sales and Marketing BMS, Cancer, breast cancer
Bristol-Myers Squibb's breast cancer drug Ixempra has suffered a setback in the EU over safety concerns.The Committee for Medicinal Products …
Roche maintains sales growth for Q3
November 2, 2007Sales and Marketing BMS
Third quarter figures show Roche's top-selling products have all posted double-digit advances on the same period in 2006. Growth for …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
